Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis
The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as ... Read More
Sanofi enters exclusive talks with CD&R over $17bn Opella deal
Sanofi has confirmed its exclusive negotiations with Clayton, Dubilier & Rice (CD&R) for the sale of a 50% stake in its consumer healthcare business, Opella. ... Read More
Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing ... Read More
EMA approves Dupixent as first biologic for COPD with elevated eosinophils
The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease ... Read More
Lupin Limited expands global specialty portfolio with strategic acquisitions
Global pharmaceutical leader Lupin Limited (Lupin) has announced the completion of a strategic acquisition through its European hub, Lupin Atlantis Holdings SA. The company has ... Read More
Sonofi and Sobi get Altuviiio FDA approval to treat hemophilia A
Sonofi and Sobi have secured the approval of the US Food and Drug Administration (FDA) for their Altuviiio for hemophilia A treatment. Altuviiio, previously known ... Read More
Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More
Regeneron gets Libtayo approval in Japan for advanced cervical cancer
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for ... Read More
Innovent Biologics, Sanofi to expedite development of cancer drugs in China
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China ... Read More
Adagene, Sanofi signs collaboration and license deal worth up to $2.5bn
Adagene, a US-based biopharma company, has signed a collaboration and license deal worth up to $2.5 billion plus royalties with Sanofi to produce masked monoclonal ... Read More